7VI0

Crystal structure of EP300 HAT domain in complex with compound 11

Summary for 7VI0

• Entry DOI: 10.2210/pdb7vi0/pdb
• Descriptor: Histone acetyltransferase p300, ZINC ION, (4S)-N-(3H-indazol-4-yl)-3-[1-(4-methoxyphenyl)cyclopentyl]carbonyl-1,1-bis(oxidanylidene)-1,3-thiazolidine-4-carboxamide, ... (4 entities in total)
• Functional Keywords: epigenetics, sbdd, histone acetyltransferase, transferase
• Biological source: Homo sapiens (Human); More
• Total number of polymer chains: 2
• Total formula weight: 106169.01

Authors

Takahashi, M.,Hanzawa, H. (deposition date: 2021-09-24, release date: 2022-04-27, Last modification date: 2023-11-29)

Primary citation

Kanada, R.,Kagoshima, Y.,Asano, M.,Suzuki, T.,Murata, T.,Haruta, M.,Takahashi, M.,Ubukata, O.,Hashimoto, K.,Obata, K.,Kihara, K.,Kuroha, M.,Banjo, T.,Togashi, N.,Sato, K.,Yamamoto, Y.,Suzuki, K.,Isoyama, T.,Tominaga, Y.,Higuchi, S.,Naito, H.
Discovery of EP300/CBP histone acetyltransferase inhibitors through scaffold hopping of 1,4-oxazepane ring.
Bioorg.Med.Chem.Lett., 66:128726-128726, 2022

PubMed Abstract: EP300 and its paralog CBP play an important role in post-translational modification as histone acetyltransferases (HATs). EP300/CBP inhibition has been gaining attention as an anticancer treatment target in recent years. Herein, we describe the identification of a novel, highly selective EP300/CBP inhibitor, compound 11 (DS17701585), by scaffold hopping and structure-based optimization of a high-throughput screening hit 1. Compound 11 (DS17701585) shows dose-dependent inhibition of SRY-box transcription factor 2 (SOX2) mRNA expression in a human lung squamous cell carcinoma cell line LK2-xenografted mouse model.

PubMed: 35413416
DOI: 10.1016/j.bmcl.2022.128726

Experimental method

X-RAY DIFFRACTION (2.1 Å)